Hentze Hannes, Graichen Ralph, Colman Alan
ES Cell International, 11 Biopolis Way, #05-06 Helios Building, 138667 Singapore, Republic of Singapore.
Trends Biotechnol. 2007 Jan;25(1):24-32. doi: 10.1016/j.tibtech.2006.10.010. Epub 2006 Nov 3.
Recent developments in the identification, in vitro culture and differentiation of stem cells point to the unprecedented potential of these cells, or their derivatives, to cure degenerative disorders. Human embryonic stem cells (hESC) offer the particular advantage of prolonged proliferative capacity and great versatility in the lineages that can be formed in culture. Translating these advantages into clinical benefits faces many challenges, including efficient differentiation into the desired cell type(s), maintaining genetic stability during long-term culture and, finally, ensuring the absence of potentially tumorigenic hESC from the final product. It is this final safety issue that will form the focus of this review.
干细胞鉴定、体外培养和分化方面的最新进展表明，这些细胞或其衍生物在治疗退行性疾病方面具有前所未有的潜力。人类胚胎干细胞（hESC）具有增殖能力持久以及在培养中可形成的谱系具有高度多样性的独特优势。将这些优势转化为临床益处面临诸多挑战，包括高效分化为所需的细胞类型、在长期培养过程中维持遗传稳定性，以及最终确保最终产品中不存在具有潜在致瘤性的hESC。正是这一最后的安全性问题将成为本综述的重点。
